Announcement

Collapse
No announcement yet.

Res Sq . Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Res Sq . Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform


    Res Sq


    . 2020 Jul 17;rs.3.rs-40198.
    doi: 10.21203/rs.3.rs-40198/v1. Preprint
    Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform

    Flavia Chiuppesi, Marcela D? Alincourt Salazar, Heidi Contreras, Vu Nguyen, Joy Martinez, Soojin Park, Jenny Nguyen, Mindy Kha, Angelina Iniguez, Qiao Zhou, Teodora Kaltcheva, Roman Levytskyy, Nancy Ebelt, Tae Kang, Xiwei Wu, Tom Rogers, Edwin Manuel, Yuriy Shostak, Don Diamond, Felix Wussow

    Abstract

    Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a novel vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.


Working...
X